Tyler Bishop | Voluntary Public Medical Records

Updated labs and tests for Tyler open sourced (with most records included from the past 8 years)

Name
Tyler Bishop
DOB
05/26/1987
Age
38 years
Sex
Male
Location
San Diego, CA
Records Span
2017-2026
PUBLIC On Purpose
Test History Timeline
12/18/2017
CBC, CMP, Lipids
08/28/2018
Allergies, CBC, CMP
02/07/2020
Renal Panel, UA
04/27/2023
Allergens
11/18/2024
Rheumatology Panel
07/17/2025
CBC, CMP
01/04/2026
Synovial Fluid
01/12/2026
C1, Tryptase
01/16/2026
Coagulation
01/19/2026
LDH Isoenzymes
Key Health Metrics (Latest: 01/19/2026)
Glucose
77
Reference: 70-99 mg/dL
Creatinine
1.02
Reference: 0.76-1.27 mg/dL
eGFR
96
Reference: >59 mL/min/1.73
BUN
13
Reference: 6-20 mg/dL
Potassium
4.6
Reference: 3.5-5.2 mmol/L
AST
27
Reference: 0-40 IU/L
Total IgE
9
Reference: 0-100 IU/mL
Allergen Status
All Negative
No detectable allergen reactions
Recent Notable Findings
Test Latest Result Reference Range Status Notes
Glucose 77 mg/dL 70-99 Normal Improved from 87 in July 2025
LDH Total 231 IU/L 121-224 HIGH Slightly elevated (Jan 19, 2026); LD fractions show normal distribution
AST 27 IU/L 0-40 Normal Significantly improved from 62 in Nov 2024
ALT 30 IU/L 0-44 Normal Major improvement from 95 in Nov 2024
Total Bilirubin 1.1 mg/dL 0.0-1.2 Normal Improved from 1.5 in Aug 2018
Vitamin B12 1728 pg/mL 232-1245 HIGH Elevated (Aug 2018), suggests supplementation
LD Isoenzymes / LDH Fractions (01/19/2026) ⚠️

These tests measure the different "fractions" of Lactate Dehydrogenase to pinpoint tissue damage.

Test Result Reference Interval Status
LDH Total 231 IU/L 121–224 IU/L HIGH
LD Fraction 1 (Heart, RBC) 31% 17–32% Normal
LD Fraction 2 (Heart, RBC) 34% 25–40% Normal
LD Fraction 3 (Lung, Lymph) 20% 17–27% Normal
LD Fraction 4 (Liver, Muscle) 8% 5–13% Normal
LD Fraction 5 (Liver, Muscle) 7% 4–20% Normal
Analysis: While total LDH is slightly elevated at 231 IU/L, all individual LD fractions are within normal limits. The normal LD1/LD2 ratio rules out acute myocardial infarction or hemolysis as causes. Normal LD4/LD5 suggests no active liver or muscle damage. The mild LDH elevation may be due to minor cellular turnover or sample handling. Continue monitoring.
⚠️ Critical Finding: Synovial Fluid Analysis (01/04/2026)

Source: Right Elbow — This report indicates hemarthrosis (bleeding into the joint), which is a significant finding.

Test Result Reference Status
Appearance Bloody Clear ABNORMAL
Color Red Yellow ABNORMAL
RBC Count 3,197,000 /mcL < 2,000 /mcL CRITICAL HIGH
Nucleated Cells 2,570 /mcL 0–200 /mcL HIGH
Neutrophils 68% < 25% HIGH
⚠️ Clinical Significance: The synovial fluid analysis reveals hemarthrosis with extremely elevated RBC count (3.2 million vs normal <2,000). Elevated nucleated cells and neutrophils suggest an inflammatory response to the blood in the joint space.

Possible causes include: Trauma, coagulopathy, anticoagulant therapy, hemophilia, or pigmented villonodular synovitis. Factor V Leiden and Antiphospholipid panel were subsequently tested and both negative. Requires clinical correlation and may warrant rheumatology or hematology follow-up.
Complete Blood Count (CBC) - Historical Data
Test Date WBC (x10E3/uL) RBC (x10E6/uL) Hemoglobin (g/dL) Hematocrit (%) MCV (fL) MCH (pg) Platelets (x10E3/uL)
12/18/2017 5.1 4.60 13.8 40.0 87 30.0 247
08/28/2018 4.7 4.41 13.4 38.4 87 30.4 222
11/18/2024 4.8 4.46 13.5 40.2 90 30.3 288
07/17/2025 5.0 4.64 14.1 42.7 92 30.4 272
Notes: All CBC values remain within normal reference ranges. Hemoglobin and hematocrit show modest increase in 2025, suggesting healthy blood composition. WBC, RBC, and platelet counts all normal, indicating no anemia or clotting disorders.
Comprehensive Metabolic Panel (CMP) - Historical Data
Test Date Glucose (mg/dL) BUN (mg/dL) Creatinine (mg/dL) eGFR Sodium (mmol/L) Potassium (mmol/L) Chloride (mmol/L) Calcium (mg/dL)
12/18/2017 90 10 1.00 101 - - - -
08/28/2018 86 10 1.06 93 141 4.3 100 9.9
02/07/2020 92 7 1.02 97 140 5.1 99 9.9
11/18/2024 90 16 1.14 85 139 4.4 99 9.9
07/17/2025 87 17 1.14 84 139 5.3 101 10.1
01/16/2026 77 13 1.02 96 139 4.6 98 10.2
Trends & Notes: Glucose levels stable and normal (77-92 mg/dL). Creatinine stable around 1.0-1.14, indicating consistent kidney function. eGFR is healthy (>59 mL/min/1.73). BUN shows increase from 2018 to 2025, then improved in 2026. Electrolytes (Na, K, Cl, Ca) all within normal ranges throughout record period.
Liver Function Panel - Historical Data
Test Date AST (IU/L) ALT (IU/L) ALP (IU/L) Bilirubin (mg/dL) Albumin (g/dL) Total Protein (g/dL)
08/28/2018 37 24 52 1.5* 4.9 6.8
02/07/2020 - - - - 4.7 -
11/18/2024 62* 95* 79 1.1 4.7 6.6
07/17/2025 31 30 77 1.0 4.6 6.6
01/16/2026 27 - 86 1.1 4.8 6.8
Trends & Notes: *Alert: AST and ALT were significantly elevated in Nov 2024 (62 and 95 IU/L respectively), but improved dramatically by July 2025 and current values (27 and 30) are well within normal limits. This suggests either an acute condition that resolved or excellent treatment response. Total bilirubin was slightly elevated in Aug 2018 (1.5) but normalized subsequently. Albumin and total protein consistently normal, indicating good liver synthetic function.
C1 Esterase & Tryptase Testing (01/12/2026)

These tests evaluate for angioedema or mast cell activation disorders.

Test Result Reference Interval Status
C1 Esterase Inhibitor 29 mg/dL 21–39 mg/dL Normal
Complement C1q, Quantitative 12.6 mg/dL 10.2–20.3 mg/dL Normal
Tryptase 6.0 ug/L 2.2–13.2 ug/L Normal
Interpretation: All values within normal limits. Normal C1 Esterase Inhibitor level rules out hereditary angioedema (HAE). Normal Tryptase level rules out systemic mastocytosis and suggests no baseline mast cell activation disorder. These tests were likely ordered to evaluate unexplained swelling or allergic-type symptoms.
Immune, Autoimmune & Infectious Disease Screening (11/18/2024)
Test Result Reference Range Status
HBsAg (Hepatitis B Surface Antigen) Negative Negative Normal
HCV Ab (Hepatitis C Antibody) Non Reactive Non Reactive Normal
Hepatitis B Core Ab, Total Negative Negative Normal
Hepatitis B Surf Ab Quant 34415.0 mIU/mL >10 (Immunity) Immune
QuantiFERON-TB Gold Plus Negative Negative Normal
Rheumatoid Factor (RF) <10.0 IU/mL <14.0 Negative
Anti-CCP Antibody <20 Units <20 Negative
Antinuclear Antibody (ANA) Negative Negative Negative
Sjogren's Anti-SS-A <0.2 AI 0.0-0.9 Negative
Sjogren's Anti-SS-B <0.2 AI 0.0-0.9 Negative
Smith Antibodies <0.2 AI 0.0-0.9 Negative
Anti-dsDNA Antibodies <1 IU/mL 0-9 (Negative <5) Negative
Anti-U1 RNP Antibody <20 Units <20 Negative
Anti-DFS70 Antibody <20 Units <20 Negative
HLA-B27 Negative Negative Negative
Complement C3, Serum 93 mg/dL 82-167 Normal
Complement C4, Serum 15 mg/dL 12-38 Normal
Celiac Disease (tTG IgA) <2 U/mL 0-3 Negative
Summary: All infectious disease screening tests (Hepatitis B, C, TB) negative or show immunity to Hepatitis B. All autoimmune markers (ANA, Rheumatoid Factor, Anti-CCP, connective tissue disease antibodies) are negative, effectively ruling out systemic autoimmune conditions. No evidence of celiac disease.
Allergen-Specific IgE Testing (All Dates)
Total IgE
9 IU/mL
Reference: 0-100 IU/mL | Date: 08/28/2018
Allergen Classes (Class 0 = Negative <0.10 kU/L)

Environmental Allergens

Dust Mites (D. pteronyssinus)
Class 0 (Negative) - <0.10 kU/L
Dust Mites (D. farinae)
Class 0 (Negative) - <0.10 kU/L
Cat Dander
Class 0 (Negative) - <0.10 kU/L
Dog Dander
Class 0 (Negative) - <0.10 kU/L
Cockroach (German)
Class 0 (Negative) - <0.10 kU/L
Cockroach (American)
Class 0 (Negative) - <0.10 kU/L

Grass Allergens

Bermuda Grass
Class 0 (Negative) - <0.10 kU/L
Timothy Grass
Class 0 (Negative) - <0.10 kU/L
Johnson Grass
Class 0 (Negative) - <0.10 kU/L
Rye Grass (Perennial)
Class 0 (Negative) - <0.10 kU/L
Bahia Grass
Class 0 (Negative) - <0.10 kU/L

Tree Allergens

Alder (Grey)
Class 0 (Negative) - <0.10 kU/L
Cedar (Mountain)
Class 0 (Negative) - <0.10 kU/L
Cedar (Red)
Class 0 (Negative) - <0.10 kU/L
Oak (White)
Class 0 (Negative) - <0.10 kU/L
Elm (American)
Class 0 (Negative) - <0.10 kU/L
Ash (White)
Class 0 (Negative) - <0.10 kU/L
Hickory (White)
Class 0 (Negative) - <0.10 kU/L
Birch (Common Silver)
Class 0 (Negative) - <0.10 kU/L
Cottonwood
Class 0 (Negative) - <0.10 kU/L
Walnut
Class 0 (Negative) - <0.10 kU/L
White Mulberry
Class 0 (Negative) - <0.10 kU/L
Sweet Gum
Class 0 (Negative) - <0.10 kU/L
Maple/Box Elder
Class 0 (Negative) - <0.10 kU/L
Bayberry/Sweet Gale
Class 0 (Negative) - <0.10 kU/L

Weed Allergens

Ragweed
Class 0 (Negative) - <0.10 kU/L
Mugwort
Class 0 (Negative) - <0.10 kU/L
Lamb's Quarters
Class 0 (Negative) - <0.10 kU/L
Sagebrush
Class 0 (Negative) - <0.10 kU/L
Tumbleweed (Russian Thistle)
Class 0 (Negative) - <0.10 kU/L

Mold Allergens

Aspergillus fumigatus
Class 0 (Negative) - <0.10 kU/L
Candida albicans
Class 0 (Negative) - <0.10 kU/L
Cladosporium herbarum
Class 0 (Negative) - <0.10 kU/L
Penicillium notatum
Class 0 (Negative) - <0.10 kU/L

Food Allergens

Peanut
Class 0 (Negative) - <0.10 kU/L
Tree Nut (Almond)
Class 0 (Negative) - <0.10 kU/L
Tree Nut (Cashew)
Class 0 (Negative) - <0.10 kU/L
Tree Nut (Walnut)
Class 0 (Negative) - <0.10 kU/L
Milk (Cow)
Class 0 (Negative) - <0.10 kU/L
Egg (Chicken)
Class 0 (Negative) - <0.10 kU/L
Soy
Class 0 (Negative) - <0.10 kU/L
Wheat
Class 0 (Negative) - <0.10 kU/L
Sesame
Class 0 (Negative) - <0.10 kU/L
Shellfish (Shrimp)
Class 0 (Negative) - <0.10 kU/L
Shellfish (Crab)
Class 0 (Negative) - <0.10 kU/L
Fish
Class 0 (Negative) - <0.10 kU/L
Summary: Comprehensive allergen panel shows no detectable IgE antibodies to any tested allergens. Total IgE is low (9 IU/mL, normal <100). This indicates no allergic sensitization to common environmental, food, or inhalant allergens. Patient is not at risk for typical allergic reactions from these common sources.
Genetic Profile & Pharmacogenomics
Hemochromatosis Risk (HFE Gene - CRITICAL)
HFE C282Y Variant
Heterozygous Carrier (1 copy) ⚠️
HFE H63D Variant
Negative
Clinical Risk
Carrier status - Low to moderate risk. Requires iron monitoring.
MTHFR Status (Methylenetetrahydrofolate Reductase)
C677T Variant
Heterozygous (CT)
A1298C Variant
Heterozygous (AC)
Clinical Significance
Mild reduction in enzyme activity (~65% of normal)
Coagulation Testing (01/16/2026) — Tested following Hemarthrosis

Factor V Leiden and Antiphospholipid antibodies tested to evaluate potential coagulopathy following joint bleeding.

Factor V Leiden (R506Q Mutation)
Negative (Normal/Normal) ✓
Clinical Interpretation
No mutation detected. Patient does not have Factor V Leiden thrombophilia.
Antiphospholipid Antibody Panel (01/16/2026)

Comprehensive panel to rule out antiphospholipid syndrome (APS) as cause of bleeding/clotting abnormalities.

Cardiolipin Ab IgG
Negative ✓
Cardiolipin Ab IgM
Negative ✓
Cardiolipin Ab IgA
Negative ✓
Beta-2 Glycoprotein IgG
Negative ✓
Beta-2 Glycoprotein IgM
Negative ✓
Beta-2 Glycoprotein IgA
Negative ✓
Panel Interpretation
All antiphospholipid antibodies negative. No evidence of antiphospholipid syndrome.
Cardiovascular Risk (Thrombosis & Hemostasis)
Factor V Leiden
Negative (confirmed 01/16/2026)
Factor II Prothrombin G20210A
Negative
PAI-1 (Plasminogen Activator Inhibitor-1)
4G/5G Heterozygous
Risk Assessment
Low thrombotic risk; no major clotting disorders detected
Pharmacogenomics (Drug Metabolism)
CYP3A4 (Major Drug Metabolizer)
Normal Metabolizer (*1/*1)
CYP2D6 (Antidepressant/Opioid Metabolism)
Normal Metabolizer (*1/*1)
CYP2C19 (SSRI/Warfarin Metabolism)
Intermediate Metabolizer (*1/*2)
TPMT (Thiopurine Metabolism)
Normal Activity
ALDH2 (Alcohol Metabolism)
Normal Metabolizer
Other Notable Genetic Markers
ApoE (Apolipoprotein E)
ε3/ε3 (Normal lipid metabolism)
ACE (Angiotensin-Converting Enzyme)
II Genotype (Associated with better cardiovascular fitness)
Lactase Persistence
CC Genotype (Lactose tolerant)
CETP (Cholesterol Ester Transfer Protein)
TaqIB: BB Genotype (Associated with protective HDL levels)
Summary: Genetic profile shows generally favorable markers with normal drug metabolism for most medications. MTHFR heterozygous status (both variants) suggests mild reduction in methylation capacity but not clinically significant. Coagulation workup (01/16/2026): Factor V Leiden negative and full Antiphospholipid panel negative — no inherited thrombophilia or APS detected. These tests were performed following hemarthrosis finding. Lipid metabolism markers (ApoE ε3/ε3, ACE II, CETP BB) are associated with better cardiovascular health outcomes. CYP2C19 intermediate metabolizer status may warrant dose adjustments for certain SSRIs or warfarin if prescribed.
Health Trends & Longitudinal Analysis
Glucose Trend (2017-2026)
Liver Enzymes Trend (AST, ALT, ALP)
Kidney Function (Creatinine, eGFR)
Blood Cell Counts (Hemoglobin, Hematocrit)
Key Alerts & Clinical Notes
Alert Type Date Finding Current Status Action Taken/Recommended
CRITICAL 01/04/2026 Hemarthrosis - Right Elbow (RBC 3.2M, Neutrophils 68%) INVESTIGATE Synovial fluid shows significant bleeding into joint. Factor V Leiden and Antiphospholipid panel both negative. Cause undetermined; requires rheumatology/hematology follow-up.
HIGH 11/18/2024 AST & ALT Significantly Elevated (62, 95 IU/L) Resolved Dramatic improvement by 07/2025; likely temporary inflammation, possible viral hepatitis or medication reaction. Recommend repeat testing if elevation recurs.
HIGH 08/28/2018 Total Bilirubin Elevated (1.5 mg/dL) Resolved Normalized by 2020; likely Gilbert's Syndrome or benign hyperbilirubinemia. No further action needed.
MODERATE 01/19/2026 LDH Total Elevated (231 IU/L, ref 121-224) MONITOR LD isoenzyme fractions all normal — rules out acute MI, hemolysis, and active liver/muscle damage. Mild elevation may be benign. Continue monitoring.
MODERATE 07/17/2025 - Present BUN Slightly Elevated (13-17 mg/dL) MONITOR Mild elevation; ensure adequate hydration. Can indicate dehydration or early kidney stress. Creatinine and eGFR normal, so kidney function preserved.
INFO 08/28/2018 Vitamin B12 Elevated (1728 pg/mL, ref 232-1245) Unchanged Suggests B12 supplementation; no pathology. Continue supplementation if clinically indicated. Recheck if symptoms of deficiency emerge.
INFO 11/18/2024 - Present Hepatitis B Immunity Confirmed (34415 mIU/mL) Protected Strong protective antibody titers from vaccination. No booster needed at this time. Recommend checking immunity status again in 10 years.
Data Archive & Historical Records

Complete list of all tests performed from 2017-2026, organized by date.

Test Date Test Type Number of Tests Key Results Status
12/18/2017 CBC, CMP, Lipids 26 tests All normal; baseline established Normal
08/28/2018 CBC, CMP, Liver, Allergen IgE 32 tests Bilirubin elevated (1.5); B12 elevated (1728); allergies negative ALERT
02/07/2020 Renal Panel, Electrolytes, UA 18 tests Kidney function normal; bilirubin normalized Normal
04/27/2023 Allergen-Specific IgE (Focused) 12 tests All allergens negative; low total IgE Normal
11/18/2024 Rheumatology Panel, CBC, Immune 48 tests AST, ALT significantly elevated (62, 95); all autoimmune negative HIGH ALERT
07/17/2025 CBC, CMP, Lipids 28 tests Liver enzymes normalized; all values improved Normal
01/04/2026 Synovial Fluid Analysis (Right Elbow) 5 tests Hemarthrosis detected; RBC 3.2M, elevated neutrophils CRITICAL
01/12/2026 C1 Esterase, Tryptase, Complement 3 tests All within normal limits; no angioedema or mast cell disorder Normal
01/16/2026 Factor V Leiden, Antiphospholipid Panel 8 tests All negative; no thrombophilia or APS detected Normal
01/19/2026 LDH Isoenzymes (LD Fractions) 6 tests LDH Total elevated (231); all fractions normal distribution MONITOR
Archive Summary: Medical records spanning 9 years (2017-2026) show overall good health trajectory with one significant finding in January 2026: hemarthrosis (bleeding in right elbow joint) detected via synovial fluid analysis. Extensive coagulation workup (Factor V Leiden, Antiphospholipid panel) returned normal, ruling out common clotting disorders. Liver enzyme elevation from Nov 2024 fully resolved. Genetic screening reveals no major disease risk factors. C1/Tryptase testing normal, ruling out angioedema disorders. Current status: Hemarthrosis requires ongoing investigation; LDH monitoring recommended.